Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) where lifetime costs and outcomes cannot be observed, outcome data have to be combined with costs. This requires that cost data be regularly updated.
Introduction
There is a tradition for economic studies in health care in Spain. 1 The Spanish Ministry of Health has sponsored two projects to propose a standard methodology for economic assessment of health interventions. The first was completed as early as 1995, but was not followed by implementation; the second resulted in the publication in 2009 of guidelines for economic evaluation developed by a large group of stakeholders including the health technology assessment (HTA) agencies from the different regions. 2 Economic studies are thus frequently published and incorporated into decision making, although they are not mandatory, despite the co-existence of several regional HTA agencies and a central agency. 3 In multiple sclerosis (MS), a number of studies have been published, including cost of illness assessments. [4] [5] [6] [7] The availability of disease-modifying treatments (DMTs) has led to changes in patient management and to focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 8, 9 A recent small study in the Northern district of Seville estimated prevalence at 90/100,000 population, up from 36 to 55/100,000 estimated earlier. 10, 11 With diagnosis possible already after a clinically isolated event, 12 one must also expect a different distribution of the type of MS and severity of the disease than 10 years ago: a larger proportion of patients with relapsing-remitting disease and thus of patients in the early stages of the disease with less disability.
It therefore is important to update the information on the burden of MS, and this study is part of a Europeanwide effort in 16 countries, endorsed by the European Platform of MS Societies (European Multiple Sclerosis Platform (EMSP)) 13 and carried out with the support of national MS societies. It uses a similar methodology as the last European survey in 2005 that also included Spain. 14, 15 
Materials and methods
The detailed methodology for this European survey is published separately. 15 We provide therefore only a short summary of the general methods and issues specific to Spain.
Data
The study aimed to estimate the costs of all health care and other resource utilisation related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement and invalidity). In addition, information on major symptoms such as fatigue and cognitive difficulties as well as health-related quality of life (HRQoL) was collected, as well as patient selfassessed disability using descriptions based on the Expanded Disability Status Scale (EDSS).
Data were collected with a standard questionnaire, at a single point in time, for a retrospective period of time. The latter was varied depending on the question in order to minimise recall bias: 1 month for use of drugs, community services and family help; 3 months for hospitalisation, consultations, tests, sick leave and relapses and 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol 5 dimensions (EQ-5D) 16 ), symptoms (fatigue and cognitive difficulties) and the effect of MS on work is related to the current day or week. For comparability across countries, 13 utilities were estimated with the original value set developed in the United Kingdom. 17 In Spain, a national tariff applying the same methodology as used for the UK tariff, with individuals from the general population, was developed as early as 1999, and we therefore also present utilities established with this local tariff. 18, 19 The handling of missing data for the cost calculation is explained in more detail in the paper describing the methods. 15 For resource use, we present actual answers without any imputation for missing answers. Also, no imputations are made for missing information on disease status, symptoms and HRQoL.
Costs
Costs are calculated in the societal perspective, including all costs regardless of who ultimately is responsible for them. Patient co-payments and patients' out-of-pocket expenses are thus included.
The cost of a relapse is calculated as the difference in quarterly costs between patients with or without a relapse and an EDSS score of 0 to 6; patients who were unsure were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in the calculation, as these are unlikely to be affected within 3 months.
Unit costs for the individual resources were taken from public sources, 15 and results are reported in EUR 2015.
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented in sufficient numbers to permit analysis, rather than a prevalence sample. This allows highlighting how costs and HRQoL change as the disease progresses and provides the necessary data for costeffectiveness analysis of treatments that are expected to change the course of the disease. Mean results may thus not be representative and should neither be extrapolated directly to national costs nor be compared directly to the results in earlier studies. We therefore report results by disease severity groups only (mild MS EDSS 0-3, moderate MS EDSS 4-6.5 and severe MS EDSS 7-9).
Data collection
In anonymous surveys, it is difficult to include a fully representative patient population, and changes in the management of MS, in particular earlier diagnosis, have increased this challenge. In addition, participation will depend heavily on the methods used for the survey: collecting data in MS centres tends to overestimate the number of patients with early but severe disease and on treatment with DMTs; 20 collecting data from members in patient organisations may lead to the opposite. Internet surveys will bias towards younger patients with better education, while postal mailing may bias towards older patients.
The majority of the Spanish participants in the study presented here were members of two Spanish patient associations: Esclerosis Múltiple España (EME) and the Asociación Española de Esclerosis Múltiple (AEDEM-COCEMFE). Patients were invited by e-mail, on the websites, via social media and with newsletters to participate in the survey. The response rate was, however, disappointing, despite reminders. In order to increase the sample, we added 78 consecutive patients presenting at the Neurology Department of the Hospital Universitario Clinico San Carlos in Madrid.
Results
A total of 462 evaluable responses were received. All patients invited by mail answered electronically (83%), while the patients in the hospital completed paper questionnaires on site. Although all geographical regions are represented, the sample is heavily biased towards an urban population, in particular Madrid (45%). This was expected, considering the inclusion of the patients from the hospital in Madrid. However, even when excluding these patients, Madrid was overrepresented (34% vs 14% expected). Consequently, all other regions had lower proportions of participants than expected, in particular, however, Cataluña (5% vs 16% expected). 21 Thus, our results have to be considered in light of a predominantly urban population. Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Spain ranged from 19 to 85 years (mean = 43 years, median = 42 years, standard deviation (SD) = 10.7 years). Women represented 67% of the sample; 89% lived with their family and only 5 patients lived in a nursing home at the time of the survey. Education levels were higher than in the general population of a similar age: 7% of patients had basic education, 41% had a secondary or a professional degree and 52% reported a university degree. This compares to 38% of the population between 25 and 54 years with tertiary education in 2015 22 and is likely explained by the urban population and a majority of electronic answers.
Almost all patients in the sample were below retirement age (defined as effective retirement age, 63 years 23 ): 443 patients (96%). Of these, 199 patients (45%) were employed or self-employed. Two patients above retirement age also worked, bringing this group to 201 patients (or 44% of the full sample), with a mean age of 41 years. This compares to an employment rate of 62% in the general population between 20 and 64 years in 2015 24 and to 73% in the Madrid area in 2013. 25 However, 61% of employed patients worked part time, on average 30 h per week, and 75% of these did so due to MS. In the general population in Spain, only 15.5% of employed work part time, confirming indeed the effect of MS not only on employment but also on working time. 26 In addition, 14 patients (7%) of employed patients were on long-term absence. Shortterm sick leave during the past 3 months was reported by 15 patients (8%), with a mean duration of 23 days.
Employment decreased rapidly with advancing disease, as shown in Figure 1 . Of non-employed patients below retirement age, 37% indicated MS as the reason for leaving the workforce. Indeed, even in the very low EDSS range with no disability, between 30% and 50% of patients did not work.
Most employed patients felt that MS affected their productivity at work (72%), while 20% indicated that they had no problems related to work and 8% had not answered this question. The severity of the effect covered the entire visual analogue scale (VAS) range from 0 to 10, with a mean of 3.6 (SD = 3.2; Figure 2 ). Fatigue was considered the most bothersome symptom (64%), followed by difficulties with thinking (29%), low mood (27%), mobility (25%) and pain (20%).
Disease characteristics
Data on disease characteristics are summarised in Table 1 . As a consequence of the young age of the Spanish sample, the mean EDSS was low (3.4, SD = 2.5), and the group with early or mild disease was very large. The mild group represented 58% of the sample, the moderate group 29% and the severe group 11% (2% missing). However, the number of patients at most EDSS levels exceeded 30, with the exception of EDSS 9 where only one patient had answered.
In line with the low mean EDSS score, a majority of patients (73%) had relapsing-remitting MS (RRMS), and only 15% had secondary progressive MS (SPMS) and 7% primary progressive MS (PPMS), with 5% missing. This does not represent disease-type prevalence and we therefore did not include the disease course in our analyses and focussed on EDSS levels instead. Nevertheless, the high proportion of RRMS and the young age may partly explain that DMTs were used by 78% of the sample, with usage declining with higher EDSS levels, as expected (Table 1) . Among users, 29% were on their first DMT treatment; firstgeneration DMTs were used by 45% of users (Table 2) .
Relapses in the preceding 3 months were reported by 61 patients (13%), of which one-third occurred in the past month (Table 1) . However, 111 patients (24%) were unsure whether they had a relapse or not, and we assumed that the answer was no. Thus, the mean relapse rate over a 3-month period was estimated at 0.2 (SD = 0.5). Corticosteroids were administered to two-thirds of patients with relapses, half of the time as infusion.
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for the majority of patients, and both were related to disease severity ( Figure 2 ). Fatigue was present in 92% of patients (2% missing). The mean VAS score was 5.7 (SD = 2.7) for the whole sample, 4.9 for patients with mild disease, 6.8 for patients in the moderate group and 7.4 for patients in the severe group. Cognitive difficulties were present in 64% of all patients (1% missing). The mean VAS score in the group with difficulties was 5.0 (SD = 2.3) overall, 4.4 in the mild group, 5.7 in the moderate group and 6.1 in the severe group. For the full-study sample (assigning 0 to the group with no problems), the mean score was 3.3 (SD = 3.0), with scores of 2.8 in the mild and 4.0 in the moderate and severe groups.
All five domains of HRQoL included in the EQ-5D displayed problems for a large proportion of patients: pain/discomfort for 63%, usual activities for 62%, anxiety/depression for 55%, mobility for 54% and self-care for 26%. Both the severity and the affected domains changed with advancing disease. Self-care was unaffected in patients with mild disease, but declined rapidly with advancing disability. Mobility, pain and usual activities presented problems for almost all patients already with moderate disease; most noticeably, however, anxiety/depression was present in more than 50% of the patients at all levels of disease severity (Figure 3 ).
Utility
Utility scores declined with increasing EDSS ( Figure  4 ). Mean utility in this specific sample of patients was 0.626 and 0.652 using the UK and Spanish value sets, respectively. [17] [18] [19] Utilities are almost identical using the two value sets, with slightly higher utilities in the early EDSS stages but lower scores in advanced EDSS: Expanded Disability Status Scale. Proportion of patients below retirement age who are employed or self-employed; 443 patients (96%) were below retirement age, and of these, 45% were employed or self-employed. Among these, 14 patients were on long-term absence. EDSS 9 was not included in this figure as there was only one patient (below retirement age and not working). stages. A similar picture emerged in the French study of this series and may be due to methodological differences in the development of the value sets and different preferences compared to the UK study.
Resource utilisation
Resource utilisation is presented in 
EDSS: Expanded Disability Status Scale.
Proportions of patients at different levels of disease severity experiencing difficulties in the five domains of the EuroQol 5 dimensions (EQ-5D). Problems were limited in mild disease but increased very rapidly with worsening disability. Self-care was least affected for the longest time. Interestingly, anxiety/depression was present with similar severity at all stages of the disease.
used by 91% of patients during the past month. Drugs other than DMTs (including corticosteroids) were used by 34% of patients, predominantly treatments for walking, spasticity and pain (27%) and depression (10%). Non-prescription drugs were purchased by 40% of patients.
Investments in equipment and devices to aid patients' mobility were made during the past 12 months for or by 25% of patients, most often for modification to the house or the car and walking/mobility aids.
Community and social services were used by 14% of patients and were basically limited to home help. Help from family was used by 45% of patients, on average 16.6 (SD = 11.7) days per month and 6.3 (SD = 7.0) hours per day. Both community services and informal care were related to disease severity ( Figure 5 ).
Costs
Total mean annual costs per patient for patients with mild, moderate and severe disease and by EDSS score are presented in Figure 6 and Table 4 .
The average cost of a relapse for patients with an EDSS between 0 and 6 was estimated at €2044. All types of costs increased during a relapse, with hospital care representing 37% of the additional costs, informal care 29% and short-and long-term sick absence 18% (Figure 7 ).
Discussion
This study provides an update to the current understanding of the burden of MS on patients, the health care system, and society in general in Spain based on a cross-sectional survey conducted in 2016.
The Spanish sample was young, despite the fact that most participants came from patient associations. Close to half of the patients came from Madrid, which cannot be explained solely by the participation of a Madrid hospital in the enrolment. Rather it may be related to the fact that the members of the patient associations were invited electronically and that the information was collected online leading to a younger and well-educated population. Nevertheless, the sample was well spread over the entire range of disability (except EDSS 9).
Almost all patients were of working age, which illustrates fully the effect of MS on work life. Even in this young sample, employment is around 20% lower than in the population, and part-time work due to MS was around 30% lower than the general population. EDSS: Expanded Disability Status Scale. Utility by EDSS level estimated with the EQ-5D using both the UK and Spanish value sets. [17] [18] [19] (EDSS 9 not presented as there was only one patient at that level). Utility is calculated by relating the scores of the five domains (1 = no problems; 2 = some problems; 3 = severe problems) to a health state valuation system established with the general population. The differences in the valuations may be partly due to methodological differences and partly to specific national characteristics. Disease symptoms and utility were very similar to those found in all the other countries of the survey, attesting to the fact that the severity of the disease affects patients in the same way regardless of jurisdiction or heath care systems. Interestingly, in all countries of the survey, a substantial number of patients, generally around 20%, were unsure whether they had had a relapse in the past 3 months or not, despite the description in the questionnaire. Considering the high level of education of the Spanish sample, this may be somewhat surprising. However, the same lack of understanding of relapses is often observed in clinical practice as well and might point to a need for more precise disease information to be communicated to the patient.
Resource utilisation reflects the organisation of the Spanish health care system, but certain tendencies are Mean total annual costs per patient by level of EDSS. (EDSS 9 is not presented as there was only one patient at that level.) Total costs increase with disease severity, but the type of resources changes. DMTs completely dominate costs in very early disease, but production losses start already at EDSS 2 and represent a major part of costs as disability progresses. In severe disease, costs are dominated by hospitalisation, informal care and production losses. 27 Consultations with neurologists have remained at a similar level, with 65% of patients seeing a neurologist in the past 3 months, indicating good access to care in Spain. However, the high consultation rate may also be influenced by the characteristics of our sample, that is, a young urban population, with a high treatment rate, and may not fully reflect the Spanish situation.
Community services represent a very limited part of the costs in Spain, except in very severe disease where they represent about 10% of costs. On the other hand, informal care is provided by family members to almost half of the patients, representing 15% of costs in moderate disease and 27% in severe disease. However, informal care is not only associated with high costs, it also represents a high burden on caregivers. 28 The use of informal care is influenced partly by family structure (availability of and easy access to help) and partly by the absence of adequate services being offered to patients. The strong family structure in Mediterranean countries may thus have influenced this situation, where family help is readily available and may prevent the development of more community services.
An important finding of this study is the overwhelming presence of fatigue and the importance of cognitive difficulties, regardless of disease severity. Similarly, problems with anxiety and depression are present at the same level (in around 50%-60% of patients) throughout the disease. While our data do not allow investigation of causal effects, it is of note that in all 16 countries in the study, a substantial number of patients are not able to work due to MS already very early in the disease and with basically no physical disability. In Spain, 10% of patients with an EDSS of 0-3 were on invalidity or had retired early. Thus, the results of our study corroborate previous findings in German MS patients that 'invisible' symptoms such as fatigue, cognitive difficulties and mood disorders may have a strong impact on work ability. 29 In conclusion, these data characterise various aspects of the burden of MS on patients and society and capture patterns of resource utilisation that could inform future policy recommendations. In addition, these data provide input into cost-effectiveness analyses for reimbursement decisions.
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